In the last trading session, 3.96 million shares of the Unicycive Therapeutics Inc (NASDAQ:UNCY) were traded, and its beta was 2.35. Most recently the company’s share price was $0.50, and it changed around $0.09 or 20.24% from the last close, which brings the market valuation of the company to $47.09M. UNCY currently trades at a discount to its 52-week high of $1.82, offering almost -264.0% off that amount. The share price’s 52-week low was $0.20, which indicates that the current value has risen by an impressive 60.0% since then. We note from Unicycive Therapeutics Inc’s average daily trading volume that its 10-day average is 1.6 million shares, with the 3-month average coming to 2.23 million.
Unicycive Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended UNCY as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information
Instantly UNCY has showed a green trend with a performance of 20.24% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.5050 on recent trading dayincreased the stock’s daily price by 0.99%. The company’s shares are currently down -42.49% year-to-date, but still up 14.79% over the last five days. On the other hand, Unicycive Therapeutics Inc (NASDAQ:UNCY) is 19.72% up in the 30-day period. We can see from the shorts that 1.05 million shares have been sold at a short interest cover period of 0.68 day(s).
Unicycive Therapeutics Inc (UNCY) estimates and forecasts
Unicycive Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -59.10 percent over the past six months and at a 0.00% annual growth rate that is well below the industry average of 17.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -77.09%.
UNCY Dividends
Unicycive Therapeutics Inc’s next quarterly earnings report is expected to be released in November.
Unicycive Therapeutics Inc (NASDAQ:UNCY)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.73% of Unicycive Therapeutics Inc shares, and 39.92% of them are in the hands of institutional investors. The stock currently has a share float of 42.81%. Unicycive Therapeutics Inc stock is held by 30.0 institutions, with VIVO CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 9.9395% of the shares, which is about 3.47 million shares worth $1.74 million.
LOGOS GLOBAL MANAGEMENT LP, with 9.9389% or 3.47 million shares worth $1.74 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
